Money /

Money News

Related Topics:
Banking & finance
Swiss drugmaker Novartis has gained global rights over SciNeuro’s novel amyloid beta targeted antibody programme. Photo: Reuters
Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Banking & finance

TCM firms eye Hong Kong IPOs to fuel global expansion

Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

Banking & finance

Citic Securities claims top spot in Asia-Pacific investment banking for 2025

Chinese rivals fill out the rest of the top five, while US bank Morgan Stanley comes in sixth.

Advertisement
Advertisement
Advertisement
Banking & finance

The ‘biology winter’ thaws: why investors are buying Hong Kong’s biotech IPOs

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging.

Healthcare firms now account for about a fifth of the more than 300 listing applications in the city. Photo: Shutterstock
Healthcare firms now account for about a fifth of the more than 300 listing applications in the city. Photo: Shutterstock
IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

Made in China 2025

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

Swire Group

Swire Pacific’s Guy Bradley to lead Hong Kong’s Cathay Pacific, Swire Coca-Cola

Bradley succeeds Patrick Healy, who will retire from the Swire Group in May next year after over three decades of service.

Swire Pacific chairman Guy Bradley. Photo: Jonathan Wong
Banking & finance

Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

Survey of multinational corporations finds optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth.

Healthcare and life sciences are the top growth prospects over the next three to five years, according to multinational corporations. Photo: Xinhua
Healthcare and life sciences are the top growth prospects over the next three to five years, according to multinational corporations. Photo: Xinhua
Banking & finance

Gold takes centre stage as Hong Kong builds commodities ecosystem

Hong Kong plans to build an international gold trading centre as part of a wider commodities hub push.

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Banking & finance

Chinese AI, chip start-ups court global investors with Hong Kong listing plans

GigaDevice and Montage are each aiming to raise as much as US$1 billion from Hong Kong listings as early as January, report says.

The MetaX booth at the World Artificial Intelligence Conference in Shanghai, July 26, 2025. Photo: CFOTO/Future Publishing via Getty Images
Mergers & Acquisitions

Chinese brokerage CICC unveils merger details with Dongxing, Cinda

The three-way merger will create China’s fourth-largest investment bank with assets of US$128 billion.

CICC will issue some 3.1 billion new A shares at 36.91 yuan to acquire all outstanding shares in Dongxing Securities and Cinda Securities to facilitate the merger. Photo: CFOTO/Future Publishing via Getty Images
CICC will issue some 3.1 billion new A shares at 36.91 yuan to acquire all outstanding shares in Dongxing Securities and Cinda Securities to facilitate the merger. Photo: CFOTO/Future Publishing via Getty Images
MetaX

MetaX stock soars 700% in Shanghai debut as traders snap up Chinese GPU maker

MetaX closes at 829.90 yuan on Wednesday, from its IPO price of 104.66 yuan, after gaining as much as 755 per cent in intraday trading.

Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

Advertisement
Advertisement
Advertisement
Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

A number of Chinese biotech firms have clinched licensing deals with multinational companies this year. Photo: Shutterstock
A number of Chinese biotech firms have clinched licensing deals with multinational companies this year. Photo: Shutterstock
Banking & finance

Six major Hong Kong banks keep prime rates unchanged despite HKMA base rate cut

Savings rates near zero limit room for cuts as lenders protect profitability margins, analysts say.

4
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

Banking & finance

Hong Kong launches HKEX Tech 100 Index in pivot towards innovation-driven growth

Unveiling of benchmark tracking Hong Kong-listed tech firms comes amid a wave of property stock delistings.

The HKEX Tech 100 Index “covers the leading innovative sectors in our listed issuer universe that have transformed the DNA of Hong Kong’s markets”, says HKEX CEO Bonnie Chan. Photo: Handout
IPO

Exclusive | Meet the Illinois farmer sowing the seeds of the world’s biggest IPOs of 2026

Jeff Rowe, a fifth-generation Illinois farmer, runs a Chinese-owned Swiss company in Basel that is aiming for one of the world’s largest IPOs in Hong Kong, due in 2026.

Jeff Rowe, the CEO of Syngenta, at his family farm in the US state of Illinois on September 30, 2025. Photo: Anthony Collins/Handout
Jeff Rowe, the CEO of Syngenta, at his family farm in the US state of Illinois on September 30, 2025. Photo: Anthony Collins/Handout
China stock market

Moore Threads shares dazzle with fivefold jump in Shanghai debut

Moore’s shares began trading at 650 yuan amid a declining market, a 468 per cent jump from their initial public offering price of 114.28 yuan.

Banking & finance

Emerging markets to outperform US stocks as dollar weakness continues: report

Latin America, which has been an underappreciated market for many years, is the stand-out performer in emerging markets.

Millionaires and billionaires

Mainland China’s billionaire count surges as BYD and Mixue bosses power gains

The combined wealth of mainland China’s billionaires soars 22 per cent to US$1.77 trillion; Hong Kong’s ultra-rich population rises.

Wang Chuanfu of BYD is among the tech sector’s biggest wealth gainers. Photo: Handout
Help preserve 120 years of quality journalism.
SUPPORT NOW